Atlas Trials

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Clinical trial NCT07611214 · RECRUITING

Trial details

NCT number
NCT07611214
Sponsor
Aurinia Pharmaceuticals Inc.
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Lupus Nephritis
Start date
2026-04-22
Primary completion
2029-03-02
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.